drugset / Trial / NCT03384979

Optimization of Contrast Agent Dose in CT With Lean Body Weight

NCT03384979

Phase 4 Completed 274 enrolled IRCCS Policlinico S. Donato
RandomizedParallel-groupTriple-blindSupportive care

Summary

This study evaluates the different enhancement using a contrast agent dose in computed tomography based on total body weight or based on lean body weight. Half of participants will receive contrast agent dose based on their total body weight, while the other half will receive a dose based on their lean body weight. Our hypothesis is that if contrast agent is administered not basing on total body weight but on lean body weight it is possible to obtain equal or better quality of enhanced images, a reduction of the variability of contrast enhancement, and also a dose reduction in some patients (overweight ones).

Timeline

Start
2017-12-18
Primary completion
2019-02-25
Completion
2019-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Iopamidol Diagnostic / imaging agent 0.4 g/kg Intravenous
Subject Iopamidol Diagnostic / imaging agent 0.65 g/kg Intravenous

Indications

No indication recorded.